Riesgos, prevención, diagnóstico | 21 JUL 19

Cáncer de esófago

Conceptos actuales sobre el adenocarcinoma de esófago y de la unión gastroesofágica. Diagnóstico precoz, riesgos y estrategias preventivas actuales
10
23
Autor: Sri G Thrumurthy, M Asif Chaudry , Sasha S D Thrumurthy, Muntzer Mughal BMJ 2019;366:l4373
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.10.3322/caac.21492 30207593

2 Demeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res 2009;3(Suppl):S2-5.19461918

3 Hur C, Miller M, Kong CY, etal . Trends in esophageal adenocarcinoma incidence and  mortality. Cancer 2013;119:1149-58. 10.1002/cncr.27834. 23303625

4 AminMB, EdgeS, GreeneF, et al, eds. AJCC Cancer Staging Manual. 8th ed. Springer International Publishing, 2017. https://www.springer.com/gb/book/9783319406176

5 Shaheen NJ, Falk GW, Iyer PG, Gerson LBAmerican College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol2016;111:30-50, quiz 51.10.1038/ajg.2015.322 26526079

6 National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NICE guideline 12). 2015. https://www.nice.org.uk/guidance/ng12.

7 Visser E, Leeftink AG, van Rossum PSN, Siesling S, van Hillegersberg R, Ruurda JP. Waiting time from diagnosis to treatment has no impact on survival in patients with esophageal cancer. Ann Surg Oncol 2016;23:2679-89.10.1245/s10434-016-5191-6. 27012988

8 Healthcare Quality Improvement Partnership. National oesophago-gastric cancer Audit 2018. https://www.nogca.org.uk/content/uploads/2018/09/NOGCA-2018-Annual-Report-1.pdf#page=33.

9 Short MW, Burgers KG, Fry VT. Esophageal cancer. Am Fam Physician 2017;95:22-8.28075104

10 Mayo Clinic. Esophageal cancer. https://www.mayoclinic.org/diseases-conditions/esophageal-cancer/symptoms-causes/syc-20356084.

11 Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000;29:645-54.10.1093/ije/29.4.645 10922340

12 Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. SeminRadiat Oncol 2007;17:2-9.10.1016/j.semradonc.2006.09.003 17185192

13 Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184-7.10.1093/jnci/djn211 18695138

14 Cancer Research UK. Oesophageal cancer incidence statistics: Oesophageal cancer incidence by age. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/incidence#heading-One

15 National Cancer Institute. SEER cancer statistics review, 1975-2015. 2018. https://seer. cancer.gov/archive/csr/1975_2015/.

16 Cancer Research UK. Oesophageal cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/incidence#heading-One.

17 Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.10.1056/NEJM199903183401101 10080844

18 Hvid-Jensen F, Pedersen L, Drewes AMAM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 2011;365:1375-83.10.1056/NEJMoa1103042 21995385

19 Schulmann K, Sterian A, Berki A, etal . Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene 2005;24:4138-48.10.1038/sj.onc.1208598 15824739

20 Fitzgerald RC, di Pietro M, Ragunath K, etal. British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 2014;63:7-42.10.1136/gutjnl-2013-305372 24165758

21 Sikkema M, de Jonge PJF, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44, quiz e32.10.1016/j.cgh.2009.10.010 19850156

22 Weusten B, Bisschops R, Coron E, etal . Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy 2017;49:191-8.10.1055/s-0042-122140 28122386

23 Merry AHH, Schouten LJ, Goldbohm RA, van den Brandt PA. Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut 2007;56:1503-11.10.1136/gut.2006.116665 17337464

24 Chow WH, Blot WJ, Vaughan TL, etal . Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.10.1093/jnci/90.2.150 9450576

25 Locke GR3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ3rd. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999;106:642-9.10.1016/S0002-9343(99)00121-7 10378622

26 Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.10.7326/0003-4819-130-11-199906010-00003 10375336

27 Devesa SS, Blot WJ, Fraumeni JFJr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2 9827707

28 International Agency for Research on Cancer (IARC). Oespophagus. http://gco.iarc.fr/today/data/factsheets/cancers/6-Oesophagus-fact-sheet.pdf

29 World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, 2007. https:/

/www.wcrf.org/sites/default/files/english.pdf.

30 Engel LS, Chow W-H, Vaughan TL, etal . Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404-13.10.1093/jnci/djg047 13130116

31 Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev 2008;(3):CD004183.18677777

32 O’Doherty MG, Cantwell MM, Murray LJ, Anderson LA, Abnet CCFINBAR Study Group. Dietary fat and meat intakes and risk of reflux esophagitis, Barrett’s esophagus and esophageal adenocarcinoma. Int J Cancer 2011;129:1493-502.10.1002/ijc.26108 21455992

33 Freedman ND, Abnet CC, Leitzmann MF, etal . A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007;165:1424-33.10.1093/aje/kwm051 17420181

34 Siemiatycki J, Krewski D, Franco E, Kaiserman M. Associations between cigarette smoking and each of 21 types of cancer: a multi-site case-control study. Int J Epidemiol 1995;24:504-14.10.1093/ije/24.3.504 7672889

35 Fan Y, Yuan J-M, Wang R, Gao YT, Yu MC. Alcohol, tobacco, and diet in relation to esophageal cancer: the Shanghai Cohort Study. Nutr Cancer 2008;60:354-63.10.1080/01635580701883011 18444169

36 Castellsagué X, Muñoz N, De Stefani E, etal . Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer 1999;82:657-64.10.1002/(SICI)1097-0215(19990827)82:5<657::AID-IJC7>3.0.CO;2-C 10417762

37 Liyanage SS, Rahman B, Ridda I, etal . The aetiological role of human papillomavirus in oesophageal squamous cell carcinoma: a meta-analysis. PLoS One 2013;8:e69238.10.1371/journal.pone.0069238 23894436

38 Sugarbaker DJ, Ebright M, Krasna M. Overview: esophageal and proximal stomach malignancy. In: Sugarbaker DJ, ed. Adult chest surgery. McGraw-Hill Professional, 2009.

39 Lefor AT, Merino MM, Steinberg SM, etal . Computerized tomographic prediction of extraluminal spread and prognostic implications of lesion width in esophageal carcinoma. Cancer

1988;62:1287-92.10.1002/1097-0142(19881001)62:7<1287::AID-CNCR2820620707>3.0.CO;2-5 3416270

40 van Vliet EPM, Heijenbrok-Kal MH, Hunink MGM, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008;98:547-57.10.1038/sj.bjc.6604200 18212745

41 Halavaara J, Breuer J, Ayuso C, etal . Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial. J Comput Assist Tomogr 2006;30:345-54.10.1097/00004728-200605000-00001 16778605

42 Semelka RC, Martin DR, Balci C, Lance T. Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J MagnReson Imaging 2001;13:397-401.10.1002/jmri.1057 11241813

43 National Institute for Health and Care Excellence. Oesophago-gastric cancer: assessment and management in adults (NICE guideline 83). 2018. https://www.nice.org.uk/guidance/ng83.

44 Puli SR, Reddy JB, Bechtold ML, Antillon MR, Ibdah JA. Accuracy of endoscopic ultrasound in the diagnosis of distal and celiac axis lymph node metastasis in esophageal cancer: a meta-analysis and systematic review. Dig Dis Sci 2008;53:2405-14.10.1007/s10620-007-0152-3 18097752

45 Varghese TKJr, Hofstetter WL, Rizk NP, etal . The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer. Ann ThoracSurg 2013;96:346-56.10.1016/j.athoracsur.2013.02.069 23752201

46 Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.10.1053/gast.2003.50008 12512029

47 Schneider JL, Zhao WK, Corley DA. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett’s esophagus. Dig Dis Sci 2015;60:436-43.10.1007/s10620-014-3349-2. 25213077

48 Alexandre L, Clark AB, Cheong E, Lewis MP, Hart AR. Systematic review: potential preventive effects of statins against oesophageal adenocarcinoma. Aliment PharmacolTher 2012;36:301-11.10.1111/j.1365-2036.2012.05194.x 22716127

49 Jankowski JAZ, de Caestecker J, Love SB, etal. AspECT Trial Team. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet 2018;392:400-8.10.1016/S0140-6736(18)31388-6 30057104

50 PDQ Screening and Prevention Editorial Board. Esophageal cancer screening (PDQ®): health professional version. 2002. https://www.ncbi.nlm.nih.gov/pubmed/26389241

51 Ross-Innes CS, Chettouh H, Achilleos A, etal. BEST2 study group. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol 2017;2:23-31.10.1016/S2468-1253(16)30118-2 28404010

 

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí